Paula Soares

List of Publications by Year
in descending order

288 papers	12,052 citations	34105 52 h-index	34986 98 g-index
300 all docs	300 docs citations	300 times ranked	14102 citing authors

#	Article	IF	Citations
1	Frequency of TERT promoter mutations in human cancers. Nature Communications, 2013, 4, 2185.	12.8	740
2	The mTOR Signalling Pathway in Human Cancer. International Journal of Molecular Sciences, 2012, 13, 1886-1918.	4.1	662
3	BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene, 2003, 22, 4578-4580.	5.9	616
4	Melanoma treatment in review. ImmunoTargets and Therapy, 2018, Volume 7, 35-49.	5.8	483
5	TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E754-E765.	3.6	451
6	BRAF mutations are associated with some histological types of papillary thyroid carcinoma. Journal of Pathology, 2004, 202, 247-251.	4.5	334
7	E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene, 2001, 20, 1525-1528.	5.9	252
8	Mitochondrial DNA Somatic Mutations (Point Mutations and Large Deletions) and Mitochondrial DNA Variants in Human Thyroid Pathology. American Journal of Pathology, 2002, 160, 1857-1865.	3.8	243
9	Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patientsâ€™ age but not with tumour aggressiveness. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 589-595.	2.8	242
10	<i>PAX8-PPAR</i>Î³ Rearrangement Is Frequently Detected in the Follicular Variant of Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 213-220.	3.6	242
11	Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (HÃ¼rthle cell) tumours of the thyroid. British Journal of Cancer, 2005, 92, 1892-1898.	6.4	191
12	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	3.6	179
13	BRAFMutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4267-4271.	3.6	171
14	Mitochondrial Dynamics Protein Drp1 Is Overexpressed in Oncocytic Thyroid Tumors and Regulates Cancer Cell Migration. PLoS ONE, 2015, 10, e0122308.	2.5	151
15	Obesity Is Associated With Low NAD⁺/SIRT Pathway Expression in Adipose Tissue of BMI-Discordant Monozygotic Twins. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 275-283.	3.6	120
16	TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1898-1907.	3.6	113
17	Sporadicret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?. , 1998, 185, 71-78.		110
18	STAT3 negatively regulates thyroid tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2361-70.	7.1	110

#	Article	IF	Citations
19	BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 572-6.	2.8	108
20	p63 Expression in Solid Cell Nests of the Thyroid: Further Evidence for a Stem Cell Origin. Modern Pathology, 2003, 16, 43-48.	5.5	106
21	TERT Promoter Mutations in Skin Cancer: The Effects of Sun Exposure and X-Irradiation. Journal of Investigative Dermatology, 2014, 134, 2251-2257.	0.7	105
22	Telomerase promoter mutations in cancer: an emerging molecular biomarker?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 119-133.	2.8	104
23	Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma. Genes Chromosomes and Cancer, 2001, 32, 136-143.	2.8	99
24	A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Human Pathology, 2005, 36, 694-697.	2.0	93
25	Multicentre validation study of nucleic acids extraction from FFPE tissues. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 309-317.	2.8	93
26	Telomere Maintenance Mechanisms in Cancer. Genes, 2018, 9, 241.	2.4	91
27	Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 418-424.	2.8	90
28	Loss of Heterozygosity and Promoter Methylation, but not Mutation, May Underlie Loss of TFF1 in Gastric Carcinoma. Laboratory Investigation, 2002, 82, 1319-1326.	3.7	88
29	Intragenic Mutations in Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2008, 37, 333-362.	3.2	87
30	Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene, 2011, 30, 1302-1317.	5.9	87
31	Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathologica, 2005, 109, 207-210.	7.7	85
32	E-cadherin loss rather than Î²-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology, 2003, 42, 580-587.	2.9	84
33	E-cadherin gene alterations are rare events in thyroid tumors. , 1997, 70, 32-38.		81
34	Molecular and Genotypic Characterization of Human Thyroid Follicular Cell Carcinomaâ€"Derived Cell Lines. Thyroid, 2007, 17, 707-715.	4.5	81
35	The biology and the genetics of HÃ¼rthle cell tumors of the thyroid. Endocrine-Related Cancer, 2012, 19, R131-R147.	3.1	76
36	Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review. Diagnostics, 2020, 10, 39.	2.6	74

#	Article	IF	Citations
37	B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Human Pathology, 2006, 37, 781-786.	2.0	72
38	Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas. Current Genomics, 2011, 12, 609-617.	1.6	71
39	The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype. Genes, 2016, 7, 66.	2.4	70
40	Poorly Differentiated Carcinomas of the Thyroid Gland. International Journal of Surgical Pathology, 2002, 10, 123-131.	0.8	68
41	Cribriform-Morular Variant of Papillary Thyroid Carcinoma. American Journal of Clinical Pathology, 2009, 131, 134-142.	0.7	68
42	TERT biology and function in cancer: beyond immortalisation. Journal of Molecular Endocrinology, 2017, 58, R129-R146.	2.5	68
43	Molecular pathology of well-differentiated thyroid carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 447, 787-793.	2.8	67
44	HÃ¼rthle (Oncocytic) Cell Tumors of Thyroid: Etiopathogenesis, Diagnosis and Clinical Significance. International Journal of Surgical Pathology, 2005, 13, 29-35.	0.8	67
45	Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Research, 2010, 20, 107-117.	1.2	67
46	Dynamin-Related Protein 1 at the Crossroads of Cancer. Genes, 2018, 9, 115.	2.4	67
47	Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology, 1994, 24, 205-210.	2.9	66
48	mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1139-E1149.	3.6	66
49	Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. Journal of Pathology, 2001, 194, 358-366.	4.5	65
50	ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome. European Journal of Endocrinology, 2016, 174, R117-R126.	3.7	64
51	A Polymorphism in the Promoter Region of the Selenoprotein S Gene (<i>SEPS1</i>) Contributes to Hashimoto's Thyroiditis Susceptibility. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E719-E723.	3.6	63
52	Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests. Modern Pathology, 2004, 17, 819-826.	5.5	57
53	Thyroid hormone as a regulator of tumor induced angiogenesis. Cancer Letters, 2011, 301, 119-126.	7.2	56
54	NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocrine Connections, 2018, 7, 78-90.	1.9	56

#	Article	IF	Citations
55	Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT/Î²-catenin pathway. Modern Pathology, 2018, 31, 1168-1179.	5.5	54
56	Cytogenetic findings in eleven gastric carcinomas. Cancer Genetics and Cytogenetics, 1993, 68, 42-48.	1.0	53
57	BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying <i>BRAF</i>^{<i>V</i>600<i>E</i>} but not <i>KRAS</i> mutations. Journal of Pathology, 2008, 214, 320-327.	4.5	53
58	The prognostic impact of <i>TERT</i> promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. International Journal of Cancer, 2016, 139, 414-423.	5.1	50
59	Prognostic biomarkers in thyroid cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 333-346.	2.8	49
60	Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. Melanoma Research, 2016, 26, 93-99.	1.2	49
61	Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes. Cytogenetic and Genome Research, 2016, 150, 194-207.	1.1	49
62	Frontiers in endocrine disruption: Impacts of organotin on the hypothalamus-pituitary-thyroid axis. Molecular and Cellular Endocrinology, 2018, 460, 246-257.	3.2	48
63	The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 265-276.	2.8	47
64	Mitochondria and cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 481-495.	2.8	46
65	Cyclic AMP Inhibits the Proliferation of Thyroid Carcinoma Cell Lines through Regulation of CDK4 Phosphorylation. Molecular Biology of the Cell, 2008, 19, 4814-4825.	2.1	45
66	Cytogenetic findings in 18 follicular thyroid adenomas. Cancer Genetics and Cytogenetics, 1993, 67, 1-6.	1.0	43
67	Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study. Frontiers in Genetics, 2019, 10, 1237.	2.3	43
68	TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 587-600.	2.8	42
69	<i>RET/PTC</i> rearrangement is prevalent in follicular HÃ¼rthle cell carcinomas. Histopathology, 2012, 61, 833-843.	2.9	42
70	Papillary Thyroid Microcarcinoma. International Journal of Surgical Pathology, 2014, 22, 113-119.	0.8	41
71	Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma. Journal of Medical Genetics, 2002, 39, 260-265.	3.2	40
72	c-erbB-2 expression in primary gastric carcinomas and their metastases. Modern Pathology, 1992, 5, 384-90.	5.5	39

#	Article	IF	Citations
73	Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. Journal of Pathology, 2005, 206, 305-311.	4.5	38
74	Stimulated Thyroglobulin at Recombinant Human TSH-Aided Ablation Predicts Disease-free Status One Year Later. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4364-4372.	3.6	38
75	Hobnail Variant of Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2017, 41, 854-860.	3.7	38
76	Impact of<i>EGFR</i>Genetic Variants on Glioma Risk and Patient Outcome. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2610-2617.	2.5	37
77	Benign and malignant thyroid lesions show instability at microsatellite loci. European Journal of Cancer, 1997, 33, 293-296.	2.8	36
78	Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 492-499.	4.1	36
79	Coexistence of <i>TERT</i> Promoter and <i>BRAF</i> Mutations in Papillary Thyroid Carcinoma: Added Value in Patient Prognosis?. Journal of Clinical Oncology, 2015, 33, 667-668.	1.6	36
80	OXPHOS dysfunction regulates integrin-Â1 modifications and enhances cell motility and migration. Human Molecular Genetics, 2015, 24, 1977-1990.	2.9	35
81	H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid. Oncogene, 2006, 25, 4620-4627.	5.9	34
82	Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert Opinion on Therapeutic Targets, 2012, 16, 689-705.	3.4	34
83	Cribriform-Morular Variant of Papillary Thyroid Carcinoma Displaying Poorly Differentiated Features. International Journal of Surgical Pathology, 2013, 21, 379-389.	0.8	34
84	Orthovanadate-induced cell death in RET/PTC1-harboring cancer cells involves the activation of caspases and altered signaling through PI3K/Akt/mTOR. Life Sciences, 2011, 89, 371-377.	4.3	33
85	mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell and Melanoma Research, 2011, 24, 254-257.	3.3	33
86	Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. British Journal of Ophthalmology, 2011, 95, 715-719.	3.9	33
87	Selenium and Selenoproteins in Immune Mediated Thyroid Disorders. Diagnostics, 2018, 8, 70.	2.6	33
88	Polymorphisms in the TNFA and IL6 Genes Represent Risk Factors for Autoimmune Thyroid Disease. PLoS ONE, 2014, 9, e105492.	2.5	33
89	Cystic Tumor of the Atrioventricular Node of the Heart Appears to Be the Heart Equivalent of the Solid Cell Nests (Ultimobranchial Rests) of the Thyroid. American Journal of Clinical Pathology, 2005, 123, 369-375.	0.7	32
90	C-Cell-Derived Calcitonin-Free Neuroendocrine Carcinoma of the Thyroid. International Journal of Surgical Pathology, 2014, 22, 530-535.	0.8	32

#	Article	IF	Citations
91	Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoexpression and marked abnormalities of E-cadherin/catenins complex. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 498-504.	2.8	31
92	Diagnostic Criteria in Well-Differentiated Thyroid Carcinomas. Endocrine Pathology, 2006, 17, 109-118.	9.0	31
93	Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma. Familial Cancer, 2008, 7, 141-149.	1.9	31
94	mTOR activation in medullary thyroid carcinoma with RAS mutation. European Journal of Endocrinology, 2014, 171, 633-640.	3.7	31
95	Ubiquitin-Specific Proteases: Players in Cancer Cellular Processes. Pharmaceuticals, 2021, 14, 848.	3.8	31
96	GRIM-19 function in cancer development. Mitochondrion, 2011, 11, 693-699.	3.4	30
97	P63 Expression in Papillary and Anaplastic Carcinomas of the Thyroid Gland: Lack of an Oncogenetic Role in Tumorigenesis and Progression. Pathology Research and Practice, 2002, 198, 449-454.	2.3	29
98	Nrf2 Is Commonly Activated in Papillary Thyroid Carcinoma, and It Controls Antioxidant Transcriptional Responses and Viability of Cancer Cells. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1422-E1427.	3.6	29
99	Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy. Mitochondrion, 2005, 5, 333-340.	3.4	28
100	Molecular genetics of papillary thyroid carcinoma: great expectations.... Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 643-653.	1.3	28
101	MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism. European Journal of Endocrinology, 2013, 168, 119-128.	3.7	28
102	Acquisition of <i>BRAF</i> gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clinical Endocrinology, 2008, 69, 683-685.	2.4	27
103	Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). European Journal of Human Genetics, 2015, 23, 877-879.	2.8	27
104	mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression. International Journal of Molecular Sciences, 2018, 19, 1448.	4.1	27
105	TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2019, 80, 660-669.e6.	1.2	27
106	Recent Advances in Cytometry, Cytogenetics and Molecular Genetics of Thyroid Tumours and Tumour-like Lesions. Pathology Research and Practice, 1995, 191, 304-317.	2.3	26
107	A stem cell role for thyroid solid cell nests. Human Pathology, 2005, 36, 590-591.	2.0	26
108	The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. Human Pathology, 2006, 37, 562-568.	2.0	26

#	Article	IF	Citations
109	Head and neck basal cell carcinoma prevalence in individuals submitted to childhood X-ray epilation for tinea capitis treatment. European Journal of Dermatology, 2012, 22, 225-230.	0.6	26
110	CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension. BMC Cancer, 2018, 18, 68.	2.6	26
111	Thyroid nodular hyperplasia. Cancer Genetics and Cytogenetics, 1993, 69, 31-34.	1.0	25
112	Immunohistochemical study of heat shock proteins 27, 60 and 70 in the normal human adrenal and in adrenal tumors with suppressed ACTH production. Microscopy Research and Technique, 2003, 61, 315-323.	2.2	25
113	Germline Succinate Dehydrogenase Subunit D Mutation Segregating with Familial Non-RET C Cell Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4932-4937.	3.6	25
114	How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer: Table 1. Journal of Clinical Pathology, 2009, 62, 414-421.	2.0	25
115	Telomerase Activation in Hematological Malignancies. Genes, 2016, 7, 61.	2.4	25
116	The environmental contaminant tributyltin leads to abnormalities in different levels of the hypothalamus-pituitary-thyroid axis in female rats. Environmental Pollution, 2018, 241, 636-645.	7.5	25
117	Clinical Validation of a Urine Test (Uromonitor-V2Â®) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients. Diagnostics, 2020, 10, 745.	2.6	25
118	LRP1B: A Giant Lost in Cancer Translation. Pharmaceuticals, 2021, 14, 836.	3.8	25
119	The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications. Current Genomics, 2017, 18, 244-254.	1.6	25
120	Post-COVID-19 Condition: Where Are We Now?. Life, 2022, 12, 517.	2.4	25
121	Comments on: Mutations in Mitochondrial Control Region DNA in Gastric Tumours of Japanese Patients, Tamura, et al. Eur J Cancer 1999, 35, 316â€"319. European Journal of Cancer, 1999, 35, 1407-1408.	2.8	24
122	Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer, 2009, 9, 387.	2.6	24
123	â€œThe other side of the coinâ€ understanding noninvasive follicular tumor with papillary-like nuclear features in unifocal and multifocal settings. Human Pathology, 2019, 86, 136-142.	2.0	24
124	Molecular Aspects of Thyroid Calcification. International Journal of Molecular Sciences, 2020, 21, 7718.	4.1	24
125	Molecular Pathology of Non-familial Follicular Epithelialâ€"Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification. Endocrine Pathology, 2021, 32, 44-62.	9.0	24
126	Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. Oncotarget, 2016, 7, 52003-52016.	1.8	24

#	Article	IF	Citations
127	Signet Ring Cell Carcinoma of the Stomach: A Morphometric, Ultrastructural, and DNA Cytometric Study. Ultrastructural Pathology, 1992, 16, 603-614.	0.9	22
128	Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy. Expert Opinion on Therapeutic Targets, 2015, 19, 733-745.	3.4	22
129	Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 595-605.	2.8	21
130	Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma. European Journal of Endocrinology, 2016, 174, 551-561.	3.7	21
131	Fetal adenomas and minimally invasive follicular carcinomas of the thyroid frequently display a triploid or near triploid DNA pattern. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 336-342.	2.8	20
132	Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Clinical Endocrinology, 2006, 64, 659-666.	2.4	20
133	GRIM-19 in Health and Disease. Advances in Anatomic Pathology, 2008, 15, 46-53.	4.3	20
134	A follicular variant of papillary thyroid carcinoma in struma ovarii. Case report with unique molecular alterations. Histopathology, 2009, 55, 482-487.	2.9	20
135	Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes. Genes Chromosomes and Cancer, 2012, 51, 1154-1164.	2.8	20
136	Multinodular Goiter Progression Toward Malignancy in a Case of DICER1 Syndrome. American Journal of Clinical Pathology, 2018, 149, 379-386.	0.7	20
137	Clinicopathological Features as Prognostic Predictors of Poor Outcome in Papillary Thyroid Carcinoma. Cancers, 2020, 12, 3186.	3.7	20
138	AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines. PLoS ONE, 2012, 7, e46869.	2.5	20
139	Small papillary thyroid cancersâ€"is BRAF of prognostic value?. Nature Reviews Endocrinology, 2011, 7, 9-10.	9.6	19
140	A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carneyâ€"Stratakis dyad. Familial Cancer, 2012, 11, 189-194.	1.9	19
141	Unraveling molecular targets of bisphenol A and S in the thyroid gland. Environmental Science and Pollution Research, 2018, 25, 26916-26926.	5.3	19
142	TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients. International Journal of Molecular Sciences, 2020, 21, 947.	4.1	19
143	Prognostic factors in thyroid carcinomas. Verhandlungen Der Deutschen Gesellschaft FÃ¼r Pathologie, 1997, 81, 82-96.	0.5	19
144	Loss of Y chromosome in gastric carcinoma. Cancer Genetics and Cytogenetics, 1992, 61, 39-41.	1.0	18

#	Article	IF	Citations
145	An assessment of the clonality of the components of canine mixed mammary tumours by mitochondrial DNA analysis. Veterinary Journal, 2009, 182, 269-274.	1.7	18
146	Tumor-in-Tumor of the Thyroid With Basaloid Differentiation: A Lesion With a Solid Cell Nest Neoplastic Component?. International Journal of Surgical Pathology, 2011, 19, 276-280.	0.8	18
147	Primary Squamous Cell Carcinoma of the Thyroid Diagnosed as Anaplastic Carcinoma: Failure in Fine-Needle Aspiration Cytology?. Case Reports in Pathology, 2014, 2014, 1-4.	0.3	18
148	Liposomal therapies in oncology: does one size fit all?. Cancer Chemotherapy and Pharmacology, 2018, 82, 741-755.	2.3	18
149	How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer. Journal of Thyroid Research, 2011, 2011, 1-10.	1.3	17
150	Absence of theBRAFand theGRIM-19Mutations in Oncocytic (HÃ¼rthle Cell) Solid Cell Nests of the Thyroid. American Journal of Clinical Pathology, 2012, 137, 612-618.	0.7	17
151	Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas. Journal of Dermatological Science, 2014, 73, 31-39.	1.9	17
152	Characterization and antitumor activity of the extracellular carbohydrate polymer from the cyanobacterium Synechocystis Î”sigF mutant. International Journal of Biological Macromolecules, 2019, 136, 1219-1227.	7.5	17
153	The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab. Scientific Reports, 2021, 11, 6067.	3.3	17
154	Thyroid hormone receptor Î² mutations in the â€˜hot-spot regionâ€™ are rare events in thyroid carcinomas. Journal of Endocrinology, 2007, 192, 83-86.	2.6	16
155	Poorly differentiated and undifferentiated thyroid carcinomas. Turk Patoloji Dergisi, 2015, 31 Suppl 1, 48-59.	0.3	16
156	OPNa Overexpression Is Associated with Matrix Calcification in Thyroid Cancer Cell Lines. International Journal of Molecular Sciences, 2018, 19, 2990.	4.1	16
157	Analyzing the Role of DICER1 Germline Variations in Papillary Thyroid Carcinoma. European Thyroid Journal, 2020, 9, 296-303.	2.4	16
158	Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma. Cancers, 2021, 13, 2048.	3.7	16
159	Follicular thyroid carcinoma with an unusual glomeruloid pattern of growth. Human Pathology, 2008, 39, 1540-1547.	2.0	15
160	Identification of a paired box gene 8â€“peroxisome proliferator-activated receptor gamma (PAX8â€“PPARÎ³) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor. Endocrine-Related Cancer, 2010, 17, 599-610.	3.1	15
161	Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors. European Journal of Human Genetics, 2013, 21, 503-510.	2.8	15
162	A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 619-626.	2.8	14

#	Article	IF	Citations
163	Head and neck lesions in a cohort irradiated in childhood for tinea capitis treatment. Lancet Infectious Diseases, The, 2011, 11, 163-164.	9.1	14
164	Paraganglioma of seminal vesicle and chromophobe renal cell carcinoma: a case report and literature review. Sao Paulo Medical Journal, 2012, 130, 57-60.	0.9	14
165	<i>TERT</i> Promoter Mutations in Soft Tissue Sarcomas. International Journal of Biological Markers, 2016, 31, 62-67.	1.8	14
166	Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer. Hormones and Cancer, 2017, 8, 314-324.	4.9	14
167	GLUT1, MCT1/4 and CD147 overexpression supports the metabolic reprogramming in papillary renal cell carcinoma. Histology and Histopathology, 2017, 32, 1029-1040.	0.7	14
168	TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes. Scientific Reports, 2016, 6, 29714.	3.3	13
169	Hotspot TERT promoter mutations are rare events in testicular germ cell tumors. Tumor Biology, 2016, 37, 4901-4907.	1.8	13
170	TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma. Endocrine, 2018, 61, 489-498.	2.3	13
171	Reliable blood cancer cells' telomere length evaluation by qPCR. Cancer Medicine, 2020, 9, 3153-3162.	2.8	13
172	Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas. Genes, 2020, 11, 751.	2.4	13
173	Correspondence. Cancer, 1994, 73, 2879-2881.	4.1	12
174	Expression of C-erb B2 in tumours and tumour-like lesions of the thyroid. International Journal of Cancer, 1994, 56, 459-461.	5.1	12
175	Papillary thyroid carcinoma overexpresses fully and underglycosylated mucins together with native and sialylated simple mucin antigens and histo-blood group antigens. Endocrine Pathology, 1999, 10, 315-324.	9.0	12
176	Mitochondrial DNA alteration in gastric cancer. Gastroenterology, 2000, 119, 1808-1809.	1.3	12
177	A founder SDHB mutation in Portuguese paraganglioma patients. Endocrine-Related Cancer, 2013, 20, L23-L26.	3.1	12
178	Interaction of Genetic Variations inNFE2L2andSELENOSModulates the Risk of Hashimoto's Thyroiditis. Thyroid, 2019, 29, 1302-1315.	4.5	12
179	GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells. PeerJ, 2013, 1, e104.	2.0	12
180	Extended structural variation of a pentanucleotide repeat in the GSTP1 gene: characterisation in a normal population and in thyroid and gastric tumours. European Journal of Human Genetics, 2000, 8, 540-544.	2.8	11

#	Article	IF	Citations
181	In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. Endocrine-Related Cancer, 2011, 18, 401-412.	3.1	11
182	Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature. Frontiers in Molecular Biosciences, 2014, 1, 10.	3.5	11
183	Increased lymphangiogenesis in Riedel thyroiditis (Immunoglobulin G4-related thyroid disease). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 359-364.	2.8	11
184	Etiopathogenesis of oncocytomas. Seminars in Cancer Biology, 2017, 47, 82-94.	9.6	11
185	Variants of Papillary Thyroid Carcinoma: An Algorithmic Cytomorphology-Based Approach to Cytology Specimens. Acta Cytologica, 2020, 64, 288-298.	1.3	11
186	Comprehensive Assessment of TERT mRNA Expression across a Large Cohort of Benign and Malignant Thyroid Tumours. Cancers, 2020, 12, 1846.	3.7	11
187	Clonal cytogenetic abnormalities and telomeric associations in a fibroxanthoma of the stomach. Genes Chromosomes and Cancer, 1992, 5, 407-409.	2.8	10
188	Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death. Journal of Biosciences, 2011, 36, 639-648.	1.1	10
189	CDX2 Expression in Some Variants of Papillary Thyroid Carcinoma. American Journal of Clinical Pathology, 2012, 138, 907-910.	0.7	10
190	Thyroid and parathyroid tumours in patients submitted to X-ray scalp epilation during the tinea capitis eradication campaign in the North of Portugal (1950â€"1963). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 445-452.	2.8	10
191	Is Low-Dose Radiation Exposure a Risk Factor for Atherosclerotic Disease?. Radiation Research, 2018, 189, 418-424.	1.5	10
192	Tributyltin and Zebrafish: Swimming in Dangerous Water. Frontiers in Endocrinology, 2018, 9, 152.	3.5	10
193	Genomic and transcriptomic characterization of the mitochondrial-rich oncocytic phenotype on a thyroid carcinoma background. Mitochondrion, 2019, 46, 123-133.	3.4	10
194	E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. European Journal of Cancer Prevention, 1999, 8, 351.	1.3	9
195	Molecular Alterations in Sporadic Primary Hyperparathyroidism. Genetics Research International, 2011, 2011, 1-7.	2.0	9
196	Genetic alterations in thyroid tumors from patients irradiated in childhood for tinea capitis treatment. European Journal of Endocrinology, 2013, 169, 673-679.	3.7	9
197	TERT promoter mutations: a genetic signature of benign and malignant thyroid tumours occurring in the context of tinea capitis irradiation. European Journal of Endocrinology, 2017, 176, 49-55.	3.7	9
198	Sporadic retâ€rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?. Journal of Pathology, 1998, 185, 71-78.	4.5	9

#	Article	IF	Citations
199	Performance of the Bethesda System for Reporting Thyroid Cytology in Multi-Institutional Large Cohort of Pediatric Thyroid Nodules: A Detailed Analysis. Diagnostics, 2022, 12, 179.	2.6	9
200	C-erbB-2 expression in primary gastric carcinomas and their metastases. Cancer Genetics and Cytogenetics, 1992, 63, 121.	1.0	8
201	Oncocytic thyroid neoplasms: from histology to molecular biology. Diagnostic Histopathology, 2019, 25, 154-165.	0.4	8
202	Evaluation of the role of mitochondria in the non-targeted effects of ionizing radiation using cybrid cellular models. Scientific Reports, 2020, 10, 6131.	3.3	8
203	Head and neck cutaneous basal cell carcinoma: what should the otorhinolaryngology head and neck surgeon care about?. Acta Otorhinolaryngologica Italica, 2020, 40, 5-18.	1.5	8
204	The genetics of cutaneous squamous cell carcinogenesis. European Journal of Dermatology, 2018, 28, 597-605.	0.6	8
205	Clinicopathologic and prognostic significance of the expression of mucins, simple mucin antigens and histoblood group antigens in papillary thyroid carcinoma. Endocrine Pathology, 1999, 10, 305-313.	9.0	7
206	Mutated E-Cadherin: Genomic and Functional Characterization in Thyroid Cells from the KAT Family. Thyroid, 2004, 14, 902-909.	4.5	7
207	Alopecia in women submitted to childhood X-ray epilation for tinea capitis treatment. British Journal of Dermatology, 2010, 163, 643-644.	1.5	7
208	Review Article: The Familial Counterparts of Follicular Cellâ€"Derived Thyroid Tumors. International Journal of Surgical Pathology, 2010, 18, 233-242.	0.8	7
209	EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide. Journal of Cellular Biochemistry, 2011, 112, 200-210.	2.6	7
210	pmTOR is a marker of aggressiveness in papillary thyroid carcinomas. Surgery, 2016, 160, 1582-1590.	1.9	7
211	Scalp basal cell carcinoma: A different entity?. Dermatologic Therapy, 2019, 32, e12828.	1.7	7
212	Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma. Journal of Endocrinological Investigation, 2021, 44, 1837-1846.	3.3	7
213	LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer. Pathobiology, 2021, 88, 400-411.	3.8	7
214	Hashimotoâ€™s Thyroiditis in Adolescents. US Endocrinology, 2015, 11, 85.	0.3	7
215	Molecular Pathology of Thyroid Tumors: Diagnostic and Prognostic Relevance. International Journal of Surgical Pathology, 2010, 18, 209-212.	0.8	6
216	Differential Expression of HMGA1 and HMGA2 in pituitary neuroendocrine tumors. Molecular and Cellular Endocrinology, 2019, 490, 80-87.	3.2	6

#	Article	IF	Citations
217	Relevant dose of the environmental contaminant, tributyltin, promotes histomorphological changes in the thyroid gland of male rats. Molecular and Cellular Endocrinology, 2020, 502, 110677.	3.2	6
218	Subacute and low-dose tributyltin exposure disturbs the mammalian hypothalamus-pituitary-thyroid axis in a sex-dependent manner. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2022, 254, 109279.	2.6	6
219	Cystic Tumor of the Atrioventricular Node of the Heart Appears to Be the Heart Equivalent of the Solid Cell Nests (Ultimobranchial Rests) of the Thyroid. American Journal of Clinical Pathology, 2005, 123, 369-375.	0.7	6
220	Environmentally relevant dose of the endocrine disruptor tributyltin disturbs redox balance in female thyroid gland. Molecular and Cellular Endocrinology, 2022, 553, 111689.	3.2	6
221	Letter to the editor. Genes Chromosomes and Cancer, 2003, 36, 318-318.	2.8	5
222	RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation. Molecular and Cellular Endocrinology, 2015, 415, 64-75.	3.2	5
223	IL6-174 G>C Polymorphism (rs1800795) Association with Late Effects of Low Dose Radiation Exposure in the Portuguese Tinea Capitis Cohort. PLoS ONE, 2016, 11, e0163474.	2.5	5
224	Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas. Journal of Cellular Biochemistry, 2017, 118, 2064-2071.	2.6	5
225	Follicular thyroid lesions: is there a discriminatory potential in the computerized nuclear analysis?. Endocrine Connections, 2018, 7, 907-913.	1.9	5
226	Integrated Metabolomics and Transcriptomics Analysis of Monolayer and Neurospheres from Established Glioblastoma Cell Lines. Cancers, 2021, 13, 1327.	3.7	5
227	Epigenomics in Hurthle Cell Neoplasms: Filling in the Gaps Towards Clinical Application. Frontiers in Endocrinology, 2021, 12, 674666.	3.5	5
228	Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study. Journal of Experimental Pharmacology, 2021, Volume 13, 521-535.	3.2	5
229	Aggressive nonfunctioning pituitary neuroendocrine tumors. Brain Tumor Pathology, 2022, 39, 183-199.	1.7	5
230	Core I gene is overexpressed in HÃ¼rthle and non-HÃ¼rthle cell microfollicular adenomas and follicular carcinomas of the thyroid. BMC Cancer, 2004, 4, 12.	2.6	4
231	Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters, 2005, 230, 149-150.	7.2	4
232	Is <i>BRAF</i> mutation screening useful for preoperative risk stratification in papillary thyroid cancer?. Future Oncology, 2009, 5, 1225-1229.	2.4	4
233	Germline variation of the melanocortinâ€1 receptor does not explain shared risk for melanoma and thyroid cancer. Experimental Dermatology, 2009, 18, 548-552.	2.9	4
234	Melanocytic Tumour in a Black Sheep never exposed to Ultraviolet Radiation. Journal of Comparative Pathology, 2012, 146, 160-164.	0.4	4

#	Article	IF	Citations
235	Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism. International Journal of Endocrinology, 2019, 2019, 1-10.	1.5	4
236	Cancer incidence after childhood irradiation for tinea capitis in a Portuguese cohort. British Journal of Radiology, 2020, 93, 20180677.	2.2	4
237	Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer. Diagnostics, 2020, 10, 525.	2.6	4
238	A 30-Year Long-Term Experience in Appendix Neuroendocrine Neoplasmsâ€"Granting a Positive Outcome. Cancers, 2020, 12, 1357.	3.7	4
239	Rare Familial Tumours. , 2018, , 57-77.		4
240	Calcitonin receptor expression in medullary thyroid carcinoma. PeerJ, 2017, 5, e3778.	2.0	4
241	LRP1B (low density lipoprotein receptor-related protein 1B). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2014, , .	0.1	3
242	RE: TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma. Journal of the National Cancer Institute, 2015, 107, djv049-djv049.	6.3	3
243	Age-Associated Mortality Risk in Papillary Thyroid Cancer: Does BRAF Make a Real Difference?. Journal of Clinical Oncology, 2018, 36, 1455-1456.	1.6	3
244	S616-p-DRP1 associates with locally invasive behavior of follicular cell-derived thyroid carcinoma. Endocrine, 2020, 73, 85-97.	2.3	3
245	MOHS micrographic surgery for head and neck nonmelanoma skin cancer: An approach for ENT surgeons. Dermatologic Therapy, 2021, 34, e14661.	1.7	3
246	Indeterminate thyroid cytology: detecting malignancy using analysis of nuclear images. Endocrine Connections, 2021, 10, 707-714.	1.9	3
247	Mitochondria and Oncocytomas. , 2009, , 193-209.		3
248	TendÃªncias do carcinoma espinocelular cutÃ¢neo no Hospital de Gaia (2004-20013). Journal of the Portuguese Society of Dermatology and Venereology, 2018, 76, 279-286.	0.0	3
249	A Clear Cell Renal Cell Carcinoma Inhibiting the Response to Intravitreal Antivascular Endothelial Growth Factor Therapy in Wet Age-Related Macular Disease. Case Reports in Ophthalmology, 2012, 3, 443-451.	0.7	2
250	Neonatal extracorporeal membrane oxygenation: Initial experience of Hospital de SÃ£o JoÃ£o. Revista Portuguesa De Pneumologia, 2014, 20, 336-340.	0.7	2
251	The role of ablative treatment in differentiated thyroid cancer management. Expert Review of Endocrinology and Metabolism, 2017, 12, 109-116.	2.4	2
252	TERTp mutations and p53 expression in head and neck cutaneous basal cell carcinomas with different aggressive features. Scientific Reports, 2021, 11, 10395.	3.3	2

#	Article	IF	Citations
253	SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma. PLoS ONE, 2017, 12, e0180392.	2.5	2
254	Follicular Lesions with Papillary Nuclear Characteristics: Differences in Chromatin Detected by Computerized Image Analysis. Archives of Endocrinology and Metabolism, 2020, 64, 630-635.	0.6	2
255	Molecular pathology of papillary, follicular and HÃ¼rthle cell carcinomas of the thyroid. Arkhiv Patologii, 2003, 65, 45-7.	0.2	2
256	Connexin Expression in Pituitary Adenomas and the Effects of Overexpression of Connexin 43 in Pituitary Tumor Cell Lines. Genes, 2022, 13, 674.	2.4	2
257	Vascular Invasion in Thyroid and Gastric Carcinomas. Ultrastructural Pathology, 2003, 27, 41-48.	0.9	1
258	Optimization of methods to assess mitochondrial DNA in archival paraffin-embedded tissues from mammary canine tumors. Jornal Brasileiro De Patologia E Medicina Laboratorial, 2008, 44, .	0.3	1
259	Hot Topics in Papillary Thyroid Carcinoma. International Journal of Surgical Pathology, 2010, 18, 190-193.	0.8	1
260	Review of the current information on erectile dysfunction in hypertensive males with 40 years of age or older. Porto Biomedical Journal, 2020, 5, e107.	1.0	1
261	Rare Papillary Thyroid Carcinomas. , 2018, , 5-25.		1
262	Abstract 180: OPNa variant expression is associated with matrix mineralization in thyroid cancer cell lines. Cancer Research, 2018, 78, 180-180.	0.9	1
263	Re: Lohrer,H.D., Hieber,L. and Zitzelsberger,H. (2002) Differential mutation frequency in mitochondrial DNA from thyroid tumours. Carcinogenesis, 23, 1577-1582. Carcinogenesis, 2003, 24, 1155-1155.	2.8	0
264	BRAF^{V600E}mutation in papillary thyroid carcinoma: a potential target for therapy?. Expert Review of Endocrinology and Metabolism, 2009, 4, 467-480.	2.4	0
265	1121 BRAF Mutations in Thyroid Carcinomas Following Childhood Scalp Irradiation. European Journal of Cancer, 2012, 48, S270.	2.8	0
266	Metabolic modulation combined with mTOR pathway inhibition may overcame cutaneous melanoma resistance to MAPK inhibitors treatment. European Journal of Cancer, 2020, 138, S23.	2.8	0
267	Genetic Alterations and Clinical Features in Brazilian Patients With Pheochromocytomas and Paragangliomas. Journal of the Endocrine Society, 2021, 5, A83-A84.	0.2	0
268	Is thyroid gland a target of SARS-CoV-2 infection? Results of the analysis of necropsy thyroid specimens from COVID-19 patients. Endocrine Abstracts, 0, , .	0.0	0
269	<i>DGCR8</i> microprocessor defect and deregulation of its expression in thyroid cancer. European Journal of Public Health, 2021, 31, .	0.3	0
270	<i>TERT</i> Promoter Mutational Status in the Management of Cutaneous Melanoma: Comparison with Sentinel Lymph Node Biopsy. Dermatology, 2022, 238, 507-516.	2.1	0

#	Article	IF	Citations
271	Abstract 3138: Stat3 signaling in thyroid cancer. , 2010, , .		0
272	Abstract 1075: STAT3 signaling in thyroid cancer. , 2011, , .		0
273	Abstract C118: TERT promoter mutations in human gliomas.. , 2013, , .		0
274	Thyroid and Parathyroid Glands. , 2016, , 613-671.		0
275	HMGA2 as new biomarker of pituitary adenomas invasiveness?. Endocrine Abstracts, 0, , .	0.0	0
276	Telomeres in Cancer. , 2017, , 161-170.		0
277	TERT, BRAF and NRAS in the molecular profile of metastatic thyroid cancer: differences between primary and distant disease. Endocrine Abstracts, 0, , .	0.0	0
278	The usefulness of the study of sodium iodide symporter expression in thyroid primary tumors. Endocrine Abstracts, 0, , .	0.0	0
279	Genetic variation in NFE2L2 and SEPS1S associated with increased risk of Hashimoto's thyroiditis. Endocrine Abstracts, 0, , .	0.0	0
280	Other Rare Tumours and Tumour-Like Lesions. , 2018, , 79-105.		0
281	Small Cell Tumours. , 2018, , 45-56.		0
282	Therapeutic Options. , 2018, , 107-110.		0
283	Rare Follicular Tumours. , 2018, , 27-44.		0
284	The changing of clinical scenario in three consecutive generations of a Brazilian Family with Von Hippel-Lindau disease. Endocrine Abstracts, 0, , .	0.0	0
285	Editorial on â€œThe genomic landscape of TERT promoter wildtype-IDH wildtype glioblastomaâ€. Translational Cancer Research, 2018, 7, S762-S765.	1.0	0
286	MON-374 Composite Pheochromocytoma: Look and You Shall Find.... Journal of the Endocrine Society, 2019, 3, .	0.2	0
287	Genetic alterations and clinical features in 16 brazilian patients with pheochromocytomas and paragangliomas. Endocrine Abstracts, 0, , .	0.0	0
288	The Multifaceted Profile of Thyroid Disease in the Background of DICER1 Germline and Somatic Mutations: Then, Now and Future Perspectives. Journal of Molecular Pathology, 2022, 3, 1-14.	1.2	0